What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

Novartis researchers are working to extend the life of organ transplants

Novartis investigators find genetic explanations for why some young patients relapse.

A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

Chinweike Ukomadu thinks that notions about clinicians turning their backs on patients when transitioning to industry are outdated.

Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.

Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research

Novartis taps MOOC technology to share chemistry education with the world